Skip to main content

REVIEW article

Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1489015
This article is part of the Research Topic Cholesterol, inflammation and immunity View all 3 articles

Regulatory role of S1P and its receptors in sepsis-induced liver injury

Provisionally accepted
Bin Wang Bin Wang 1,2Xiaoyu Wu Xiaoyu Wu 1,2*Jiangfeng Cheng Jiangfeng Cheng 1,2*Junming Ye Junming Ye 1,3*Hongquan Zhu Hongquan Zhu 2*Liu Xiaofeng Liu Xiaofeng 2*
  • 1 Gannan Medical University, Ganzhou, Jiangxi Province, China
  • 2 First Affiliated Hospital of Gannan Medical University, Ganzhou, China
  • 3 Soochow University Medical College, Suzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    As an immune and metabolic organ, the liver affects the progression and prognosis of sepsis. Despite the severe adverse effects of sepsis liver injury on the body, treatment options remain limited. Sphingosine-1-phosphate (S1P) is a widely distributed lipid signaling molecule that binds to five sphingosine-1phosphate receptors (S1PR) to regulate downstream signaling pathways involved in the pathophysiological processes of sepsis, including endothelial permeability, cytokine release, and vascular tone. This review summarizes current research on the role of S1P in normal liver biology and describes the mechanisms by which changes in S1P/S1PR affect the development of liver-related diseases. At the same time, the pathological processes underlying liver injury, as evidenced by clinical manifestations during sepsis, were comprehensively reviewed. This paper focused on the mechanistic pathways through which S1P and its receptors modulate immunity, bile acid metabolism, and liverintestinal circulation in septic liver injury. Finally, the relationships between S1P and its receptors with liver inflammation and metabolism and the use of related drugs for the treatment of liver injury were examined. By elucidating the role of S1P and its receptor in the pathogenesis of sepsis liver injury, this review established a molecular targeting framework, providing novel insights into clinical and drug development.

    Keywords: S1P 1, S1PRs 2, sepsis 3, Immune 4, Bile acid metabolism 5, liver-intestinal circulation 6

    Received: 31 Aug 2024; Accepted: 13 Jan 2025.

    Copyright: © 2025 Wang, Wu, Cheng, Ye, Zhu and Xiaofeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaoyu Wu, Gannan Medical University, Ganzhou, 121013, Jiangxi Province, China
    Jiangfeng Cheng, Gannan Medical University, Ganzhou, 121013, Jiangxi Province, China
    Junming Ye, Gannan Medical University, Ganzhou, 121013, Jiangxi Province, China
    Hongquan Zhu, First Affiliated Hospital of Gannan Medical University, Ganzhou, China
    Liu Xiaofeng, First Affiliated Hospital of Gannan Medical University, Ganzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.